Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study.

For PFS, IPSS-R risk group (HR 2.61, 95% CI 1.42–4.80; p = 0.002) and azacitidine exposure (HR 0.34, 95% CI 0.18–0.63; p = 0.001) were independent predictors; marrow blasts were retained because they influenced the treatment estimate but did not reach statistical significance.

also in 111,027 other papers